Condition: Pancreatic Insufficiency · Cystic Fibrosis-related Diabetes · Sponsor: University of Pennsylvania
This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance when compared to randomized, double-blind 7-day administration of placebo in a cross-over fashion. We hypothesize that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage assessed during a standardized mixed-meal tolerance test.
This description comes directly from the study's public registry record.
Paola Alvarado, MSCR · 215-746-2081 · Paola.Alvarado@Pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Hospital of University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pennsylvania Center for Human Phenomic Science (CHPS) | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06995651